On July 16, 2026 Abbott (NYSE: ABT) reported financial results for the second quarter ended June 30, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Second-quarter sales increased 13.0 percent on a reported basis and 4.8 percent on a comparable basis.
Second-quarter GAAP diluted EPS of $0.53 and adjusted diluted EPS of $1.31, which excludes specified items.
Abbott reaffirms full-year 2026 comparable sales growth guidance of 6.5% to 7.5%1.
Abbott raises full-year 2026 adjusted diluted EPS guidance range to $5.45 to $5.60, compared to previous range of $5.38 to $5.58.
In April, Abbott completed enrollment in its TECTONIC U.S. pivotal trial. This trial is designed to evaluate Abbott’s investigational Coronary Intravascular Lithotripsy (IVL) System for treating severe calcification in coronary arteries prior to stent implantation.
In April, at the Heart Rhythm Society (HRS) conference, Abbott presented new late-breaking data from four clinical trials that demonstrated strong clinical outcomes across the company’s pulsed field ablation (PFA) and conduction system pacing (CSP) portfolios.
In May, Abbott announced it secured CE Mark for Libre Duo, the world’s first dual glucose-ketone biowearable sensor. By providing real-time visibility into glucose and ketone levels, this new technology helps optimize the management of diabetes by detecting rising ketone levels, which can lead to diabetic ketoacidosis, a serious health condition for people with diabetes.
In May, Abbott completed its submission to the U.S. Food and Drug Administration (FDA) seeking approval for the company’s Amulet 360 left atrial appendage (LAA) device.
In May, the American Cancer Society (ACS) issued updated colorectal cancer (CRC) screening guidelines that reaffirmed Cologuard and Cologuard Plus as preferred screening options for adults age 45 and older who are at average risk for CRC.
"Our second-quarter results reflect the momentum we are building," said Robert B. Ford, chairman and chief executive officer, Abbott. "We expect this momentum to continue and drive accelerating sales and earnings growth in the second half of the year."
SECOND-QUARTER BUSINESS OVERVIEW
Comparable sales growth:
Management believes that measuring sales growth on a comparable basis is an appropriate way for investors to best understand the underlying performance of the business. Comparable sales growth includes the prior and current year sales of Exact Sciences, a cancer diagnostics company that Abbott acquired on March 23, 2026. Comparable sales growth excludes the impact of foreign exchange and revenue in both the prior and current year related to compensation payments that Abbott’s Structural Heart business received as part of a multi-year agreement with a competitor. The final payment under this agreement was recognized in the first quarter of 2026.
Note: In order to compute results excluding the impact of exchange rates, current year U.S. dollar sales are multiplied or divided, as appropriate, by the current year average foreign exchange rates and then those amounts are multiplied or divided, as appropriate, by the prior year average foreign exchange rates.
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
5,216
871
1,660
—
2,680
International
7,377
1,273
1,432
1,499
3,173
Total reported
12,593
2,144
3,092
1,499
5,853
% Change vs. 2Q25
U.S.
22.0
(9.0)
104.8
n/a
7.0
International
7.5
1.4
5.1
8.4
10.7
Total reported
13.0
(3.1)
42.3
8.4
9.0
Total reported excl. foreign exchange impact
12.2
(3.6)
41.3
8.7
7.9
Comparable sales growth
4.8
(3.6)
2.9
8.7
8.4
U.S.
3.5
(9.0)
4.0
n/a
8.0
International
5.8
0.6
1.6
8.7
8.7
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total Company
Nutrition
Diagnostics
Established
Pharmaceuticals
Medical Devices
U.S.
9,490
1,715
2,565
—
5,203
International
14,267
2,446
2,707
2,925
6,189
Total reported
23,757
4,161
5,272
2,925
11,392
% Change vs. 1H25
U.S.
12.4
(10.3)
52.5
n/a
7.4
International
9.3
—
6.4
10.7
14.2
Total reported
10.5
(4.5)
24.7
10.7
11.0
Total reported excl. foreign exchange impact
8.2
(5.6)
22.4
8.9
8.0
Comparable sales growth
4.3
(5.6)
2.4
8.9
8.4
U.S.
3.0
(10.3)
3.0
n/a
8.3
International
5.3
(1.9)
1.6
8.9
8.5
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.
Nutrition
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Pediatric
Adult
U.S.
871
525
346
International
1,273
500
773
Total reported
2,144
1,025
1,119
% Change vs. 2Q25
U.S.
(9.0)
(10.7)
(6.4)
International
1.4
7.3
(2.0)
Total reported
(3.1)
(2.7)
(3.4)
Total reported excl. foreign exchange impact
(3.6)
(3.1)
(4.0)
Comparable sales growth
(3.6)
(3.1)
(4.0)
U.S.
(9.0)
(10.7)
(6.4)
International
0.6
6.4
(2.8)
Worldwide Nutrition sales decreased 3.1 percent on a reported basis and 3.6 percent on a comparable basis in the second quarter.
Results in the quarter reflect the impact of lower sales volumes compared to the prior year and the effect of strategic pricing actions implemented in the fourth quarter of 2025. These pricing actions, together with the launch of new products, are contributing to improving performance. Nutrition sales increased $127 million on a sequential basis compared to the first quarter of 2026.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Pediatric
Adult
U.S.
1,715
1,036
679
International
2,446
942
1,504
Total reported
4,161
1,978
2,183
% Change vs. 1H25
U.S.
(10.3)
(11.9)
(7.8)
International
—
2.4
(1.5)
Total reported
(4.5)
(5.6)
(3.5)
Total reported excl. foreign exchange impact
(5.6)
(6.4)
(4.9)
Comparable sales growth
(5.6)
(6.4)
(4.9)
U.S.
(10.3)
(11.9)
(7.8)
International
(1.9)
0.7
(3.5)
Diagnostics*
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular
Diagnostics
U.S.
1,660
377
890
393
International
1,432
1,041
29
362
Total reported
3,092
1,418
919
755
% Change vs. 2Q25
U.S.
104.8
7.5
n/a
(14.5)
International
5.1
3.4
n/a
2.0
Total reported
42.3
4.4
n/a
(7.3)
Total reported excl. foreign exchange impact
41.3
3.2
n/a
(8.0)
Comparable sales growth
2.9
3.2
13.3
(8.0)
U.S.
4.0
7.5
13.3
(14.5)
International
1.6
1.7
13.8
0.5
Worldwide Diagnostics sales increased 42.3 percent on a reported basis and 2.9 percent on a comparable basis in the second quarter.
Worldwide Core Laboratory Diagnostics results were driven by strong growth in the U.S. and Latin America.
Rapid and Molecular Diagnostics results reflect lower sales of respiratory virus tests compared to the prior year.
Cancer Diagnostics results were driven by mid-teens growth of Cologuard, which is benefiting from a growing base of both new and repeat users. Results in the quarter also reflect contributions to growth from the precision oncology and international businesses.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Core Laboratory
Cancer Diagnostics
Rapid/Molecular
Diagnostics
U.S.
2,565
724
983
858
International
2,707
1,966
32
709
Total reported
5,272
2,690
1,015
1,567
% Change vs. 1H25
U.S.
52.5
6.0
n/a
(14.1)
International
6.4
6.1
n/a
2.4
Total reported
24.7
6.1
n/a
(7.4)
Total reported excl. foreign exchange impact
22.4
3.2
n/a
(8.8)
Comparable sales growth
2.4
3.2
13.3
(8.8)
U.S.
3.0
6.0
13.2
(14.1)
International
1.6
2.2
16.5
(1.1)
*Beginning in 2026, Abbott aggregated its previously reported Rapid Diagnostics, Molecular Diagnostics, and Point of Care businesses into the Rapid and Molecular Diagnostics business. On March 23, 2026, Abbott completed the acquisition of Exact Sciences. Following the acquisition, the sales of Exact Sciences are presented as Abbott’s Cancer Diagnostics business.
Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of comparable sales growth.
Established Pharmaceuticals
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
1,499
1,164
335
Total reported
1,499
1,164
335
% Change vs. 2Q25
U.S.
n/a
n/a
n/a
International
8.4
9.8
3.7
Total reported
8.4
9.8
3.7
Total reported excl. foreign exchange impact
8.7
10.7
2.1
Comparable sales growth
8.7
10.7
2.1
U.S.
n/a
n/a
n/a
International
8.7
10.7
2.1
Established Pharmaceuticals sales increased 8.4 percent on a reported basis and 8.7 percent on a comparable basis in the second quarter.
Key Emerging Markets include several emerging countries that represent the most attractive long-term growth opportunities for Abbott’s branded generics product portfolio. Sales in these geographies increased 9.8 percent on a reported basis and 10.7 percent on a comparable basis, led by double-digit growth in several countries across the Latin America and Asia Pacific regions.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Key Emerging
Markets
Other
U.S.
—
—
—
International
2,925
2,253
672
Total reported
2,925
2,253
672
% Change vs. 1H25
U.S.
n/a
n/a
n/a
International
10.7
11.3
8.6
Total reported
10.7
11.3
8.6
Total reported excl. foreign exchange impact
8.9
10.1
4.9
Comparable sales growth
8.9
10.1
4.9
U.S.
n/a
n/a
n/a
International
8.9
10.1
4.9
Medical Devices
Second Quarter 2026 Results (2Q26)
Sales 2Q26 ($ in millions)
Total
Rhythm
Management
Electro-
physiology*
Heart
Failure
Vascular
Structural
Heart*
Neuro-
modulation
Diabetes
Care
U.S.
2,680
377
420
313
294
225
189
862
International
3,173
366
441
88
509
372
71
1,326
Total reported
5,853
743
861
401
803
597
260
2,188
% Change vs. 2Q25
U.S.
7.0
10.7
15.9
10.9
3.9
(9.8)
(2.1)
8.6
International
10.7
10.0
12.3
3.0
7.5
12.1
14.7
11.7
Total reported
9.0
10.4
14.0
9.0
6.1
2.7
2.0
10.5
Total reported excl. foreign exchange impact
7.9
9.5
13.4
8.7
5.1
1.7
1.2
9.0
Comparable sales growth
8.4
9.5
13.4
8.7
5.1
5.7
1.2
9.0
U.S.
8.0
10.7
15.9
10.9
3.9
(0.9)
(2.1)
8.6
International
8.7
8.3
11.1
1.3
5.8
10.2
11.3
9.2
Worldwide Medical Devices sales increased 9.0 percent on a reported basis and 8.4 percent on a comparable basis in the second quarter.
Sales growth in the quarter was led by low-teens growth in Electrophysiology and high-single-digit growth in Rhythm Management, Diabetes Care, and Heart Failure.
In Diabetes Care, sales of continuous glucose monitors grew 11.0 percent on a reported basis and 9.5 percent on a comparable basis.
First Half 2026 Results (1H26)
Sales 1H26 ($ in millions)
Total
Rhythm
Management
Electro-
physiology*
Heart
Failure
Vascular
Structural
Heart*
Neuro-
modulation
Diabetes
Care
U.S.
5,203
716
798
605
585
449
366
1,684
International
6,189
711
851
185
995
726
137
2,584
Total reported
11,392
1,427
1,649
790
1,580
1,175
503
4,268
% Change vs. 1H25
U.S.
7.4
11.1
14.8
11.1
6.2
(9.6)
(0.7)
9.2
International
14.2
15.9
15.7
13.5
8.7
18.1
20.4
14.0
Total reported
11.0
13.4
15.3
11.7
7.7
5.7
4.3
12.1
Total reported excl. foreign exchange impact
8.0
10.9
13.0
10.4
5.0
2.6
2.6
8.2
Comparable sales growth
8.4
10.9
13.0
10.4
5.0
6.2
2.6
8.2
U.S.
8.3
11.1
14.8
11.1
6.2
(2.2)
(0.7)
9.2
International
8.5
10.7
11.2
7.8
4.3
12.4
13.2
7.5
*Abbott’s Amplatzer Amulet Left Atrial Appendage Occluder device and related accessories were transferred from Structural Heart to Electrophysiology on January 1, 2026. As a result, $55 million of sales in the second quarter of 2025 and $101 million of sales in the first half of 2025 were moved from Structural Heart to Electrophysiology.
(Press release, Abbott, JUL 16, 2026, View Source [SID1234669268])